Genomic co-alterations and immune-related adverse events shape outcomes of thymic malignancies treated with immune checkpoint inhibitors
Molecular markers predict which rare thymus cancer patients tolerate immunotherapy toxicity while benefiting, supporting precision selection.
MD Anderson retrospective of 42 thymic malignancy patients with ICIs characterizes complex toxicity-efficacy trade-offs, where thymoma patients experienced 100% irAE rate while deriving survival benefit. Molecular biomarkers TP53 and CDKN2A show opposing prognostic associations, supporting biomarker-driven patient selection for ICI in this rare cancer.
What the study was
- Study design
- Retrospective observational study (MD Anderson, 2010–2024)
- Population
- Thymic malignancy patients treated with ICIs
- Sample size
- 42
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- NPJ Precision Oncology
Why it surfaced
Rare malignancy; NPJ Precis Oncol; biomarker-driven ICI selection fills evidence gap in thymic tumors despite small n.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.